1.. Introduction
================

The first enhancer element was identified in a DNA sequence of the SV40 virus in the 1980s, and was found to have enhanced transcriptional activity of β-globin in Oryctolagus cuniculus ([@b1-ol-0-0-11855]). Since then, novel insights into the regulatory mechanism of the genome have been accumulatively gained, due to continuous exploration ([@b2-ol-0-0-11855],[@b3-ol-0-0-11855]). It has been demonstrated that the transcriptional activation of genes is controlled by cell-type-specific proximal and distal regulatory elements, termed enhancers. As a non-coding regulatory element, an enhancer can activate gene expression through long-range chromatin interactions ([@b4-ol-0-0-11855]). Different from the typical enhancer (TE), super-enhancer (SE) can span dozens of kilo-base (kb) pairs compared with the dozens of base-pairs of the TE ([@b5-ol-0-0-11855]).

The regions of TEs and SEs are both occupied by enhancer-related molecules, including transcription factors (TFs), master cofactors, mediator complexes and RNA polymerase II (pol II) ([@b6-ol-0-0-11855]). However, compared with TEs, SEs are characterized by a wider span and more aggregation of SE-related molecules ([Fig. 1](#f1-ol-0-0-11855){ref-type="fig"}) ([@b7-ol-0-0-11855],[@b8-ol-0-0-11855]). Therefore, the SE can drive a higher level of gene transcription compared with TE, which is involved in various processes of tumorigenesis and progression ([@b9-ol-0-0-11855]). The focus of the present review includes the roles of the SE and its key complexes in cancer, with further discussion on the possible new therapies involving the SE in the targeted treatment of cancer.

2.. SEs and cancer
==================

Certain oncogenes exhibit low expression in normal cells and high expression in cancer cells via SE regulation, suggesting the significance of the SE function, particularly in the maintenance of cancer cell growth and survival ([@b10-ol-0-0-11855]--[@b13-ol-0-0-11855]). Compared with normal cells, cancer cells proactively construct SEs to drive the expression of oncogenes during tumorigenesis ([@b14-ol-0-0-11855]). Tumor mutations generally lead to the dysregulation of enhancers that normally control the signal-dependent expression of growth-associated genes, resulting in the uncontrolled proliferation of tumor cells ([@b2-ol-0-0-11855]). The results of genome wide association studies demonstrated that the majority of cancer-associated genetic variations are located outside the coding genome, and the mutation sites are often found in the putative enhancer enrichment regions ([@b15-ol-0-0-11855]). The early evidence supporting this view comes from studies in Burkitt lymphoma in which gene rearrangement caused the formation of MYC gene enhancer regions leading to MYC overexpression ([@b16-ol-0-0-11855]--[@b19-ol-0-0-11855]). Further studies have indicated that SE-driven MYC expression is critical for maintaining cell survival and proliferation in acute leukemia and neuroblastoma ([@b20-ol-0-0-11855],[@b21-ol-0-0-11855]). The inhibition of SE assembly and maintenance inhibits carcinogenic transcription and tumor growth, which suggests that the SE is a promising anti-cancer target ([@b22-ol-0-0-11855]).

In 2017, Hnisz *et al* ([@b23-ol-0-0-11855]) proposed a model to explain the roles of SE through phase separation, without, however, adequate direct evidence. Phase separation was described as a dynamic process, where the single phase consisting of the originally miscible components is decomposed into two or more different phases. Thus, phase separation represents two or more distinct liquid phases produced from a single mixed liquid phase, such as oil, whose drops are separated from the water ([@b24-ol-0-0-11855]). In 2018, Sabari *et al* ([@b25-ol-0-0-11855]) confirmed the hypothesis of the phase separation model, reporting that the transcriptional coactivators bromodomain protein 4 (BRD4) and MED1 could phase separate to form droplets at SE regions. The droplets were recruited by various types of transcriptional machinery to gather in the vicinity of the SE regions to realize the compartmentalization reaction of the transcription process. The intrinsically disordered regions (IDRs) played a pivotal role in the phase separation process. IDRs are present in RNA granule proteins that trigger the disintegration of particulate matter by phosphorylation of self-association through the action of electrostatic, polar and hydrophobic action ([@b26-ol-0-0-11855]--[@b28-ol-0-0-11855]). The transcriptional coactivator forms phase-separated particle aggregates at the SE regions, and thus the transcription device can be compartmentalized and aggregated. This provides more detailed theoretical evidence to support that SE precisely regulates oncogene transcriptional activation and drives tumor progression.

The Assay for Transposase-Accessible Chromatin with high throughput sequencing and chromatin immunoprecipitation followed by sequencing, based on high-throughput whole-genome sequencing, have identified a series of SE-driven oncogenes in various tumor cells. SE can not only play a role in gene regulation in solid tumors, such as hepatocellular, breast, esophageal and gastric tumors, but can also elevate the expression of proteins in non-solid tumors, such as lymphocytic leukemia and myeloid leukemia ([@b22-ol-0-0-11855]). SE has been confirmed to regulate a variety of well-defined oncogenes, such as c-MYC and ETS-Variant Gene 6, and to affect multiple signaling pathways, such as the MAPK and Notch signaling pathways ([@b29-ol-0-0-11855]--[@b32-ol-0-0-11855]). It is generally believed that SE can promote tumorigenesis by upregulating SE-associated oncogenes. The histone H3 acetyl K27 (H3K27ac) and histone H3 methyl K4 (H3K4me1) peaks have been confirmed in the SE regions, since SE-driven gene requires an open chromatin microenvironment ([@b33-ol-0-0-11855]). However, extensive H3K4me3 peaks have also been confirmed to occur in the regions of the tumor suppressor genes ([@b34-ol-0-0-11855]). It was therefore hypothesized that if a non-specific demethylase intervenes the histone methylation modification, it may reduce the SE-driven oncogene as well as anti-oncogene expression. Therefore, targeting histone modification is challenging to use as a targeted drug.

Apart from their involvement in protein-coding gene regulation, SEs also play unique roles in RNA \[including micro (mi)RNA, enhancer (e)RNA and long non-coding (lnc)RNA\] regulation. Suzuki *et al* ([@b35-ol-0-0-11855]) demonstrated that SE may not only promote miRNA transcription, but also enhance the cell-specific miRNA production through Drosha/DGCR8 recruitment and pri-miRNA processing through genome editing, via clustered regularly interspaced short palindromic repeats (CRISPR/Cas9). Moreover, SE-miRNAs contain many highly cell-specific and vital miRNAs (such as ESC-, muscle-, neuron-, hematopoietic-, skin- and inflammation-associated miRNAs) compared with TE-miRNAs ([@b35-ol-0-0-11855]), indicating that SE can drive the corresponding miRNAs and affect their downstream pathways. Global run-on sequencing analysis revealed that abundant eRNAs were transcribed in SE regions in lymphoblastoid cell (LCL). In addition, the knockdown of these eRNAs was found to result in LCL cell growth arrest, with MYC expression significantly declining, following the knockdown of SE-associated eRNAs of MYC ([@b36-ol-0-0-11855]), illustrating that eRNA can affect not only gene expression, but also cell growth. The SE-associated lncRNA has also been demonstrated to play a fundamental role in the regulation of enhancer activity and gene programs in cardiovascular pathology ([@b37-ol-0-0-11855]). The disordered SE regulation associated with lncRNA causes a serious physiological and pathological deterioration, such as pathological stress, remodelling and failure in the cardiovascular system ([@b37-ol-0-0-11855]). It is possible to alleviate cardiovascular disease by targeting these non-coding RNAs in the future. In hepatocellular carcinoma (HCC), the novel lncRNA HCCL5 was identified as a key oncogene, which was driven by the SE and is significantly overexpressed in human HCC tissues ([@b38-ol-0-0-11855]). In addition, HCCL5 can promote the cell proliferation, regulate the G~1~-S phase transition and affect the invasive and metastatic ability of HCC cells. Therefore, the high expression of HCCL5 may be used as a biomarker for the poor overall survival of patients with HCC. Given the important role of SE in RNA regulation, it may be attempted to control the abnormal expression of RNAs by blocking the function of SE.

In conclusion, the modifications of H3K4me1 and H3K27ac often occur in the enhancer regions of cancer cells, representing the formation of open chromatin structures, both of which are absent in normal cells ([@b39-ol-0-0-11855]). Moreover, the SE-regulated mechanism affects abnormal regulation at both the transcriptional and post-transcriptional levels, resulting in malignant transformation.

3.. Small-molecule inhibitors targeting SE for cancer treatment
===============================================================

The enhanced transcriptional activity of associated oncogenes caused by SE have been reported in various types of cancer. Therefore, blocking the SE is a viable anticancer therapy. The mechanism of action that describes the potential treatments, by targeting the SE-associated complexes, is shown in [Fig. 2](#f2-ol-0-0-11855){ref-type="fig"}. However, transcription, as a biological process that occurs universally *in vivo*, cannot be inhibited as a whole, and a high degree of specificity in clinical antitumor therapy is required to inhibit it. It is therefore necessary to find a target for the possible intervention among these small molecules that are involved in the SE mechanism. Master TFs, cofactors and histone modification markers are difficult to select as targets due to their extensive effects, while mediator complexes such as cyclin-dependent kinase 7 (CDK7) and BRD4 are relatively characteristic. Decreased CDK7 expression or BRD4 expression suppresses cancer cell growth, confirming that cancer cells are sensitive to the dosage of SE-associated mediator complexes ([@b40-ol-0-0-11855]). The inhibition of mediator complexes is considered to be a promising approach. Studies have reported that the activity of SE must depend on the interaction of key TFs, cofactors and mediator complexes. Therefore, it is theoretically feasible to design inhibitors of mediator complexes to intervene in tumor cells ([@b41-ol-0-0-11855]). Targeted inhibitors can specifically block the interaction between SE regions and their corresponding complexes, thereby rescuing the upregulated oncogene. These types of small-molecule inhibitors have been found to exert significant inhibitory effects in animal experiments ([@b42-ol-0-0-11855]--[@b44-ol-0-0-11855]). At present, the small-molecule inhibitors designed for cancer treatments include the following three types: i) CDK7 inhibitor (THZ1); ii) BRD4 inhibitor (JQ1); and iii) other inhibitors, which are summarized in [Table I](#tI-ol-0-0-11855){ref-type="table"} ([@b8-ol-0-0-11855],[@b21-ol-0-0-11855],[@b29-ol-0-0-11855],[@b35-ol-0-0-11855],[@b39-ol-0-0-11855],[@b45-ol-0-0-11855]--[@b77-ol-0-0-11855]).

Cyclin-dependent kinases (CDKs) belong to the serine/threonine kinase family, and play a crucial role in the regulation of the cell cycle and transcription process ([@b78-ol-0-0-11855]). It has been reported that CDK7 not only affects the cell cycle, but is also associated with the regulation of SE-driven oncogenes ([@b79-ol-0-0-11855]). In addition, CDK7 has recently become an attractive anti-cancer target, since CDK7 inhibitors (CDK7i) can reduce the levels of oncogenic TFs that act on SE regions ([@b51-ol-0-0-11855]). The anticancer effects of CDK7i are attributed to their effects on gene transcription or interference with the function of the SE; THZ1 is one of the most effective small-molecule inhibitors ([@b79-ol-0-0-11855],[@b80-ol-0-0-11855]). Despite the meaningful effects of THZ1 in a variety of tumors, studies have shown that THZ1 inhibits myogenic differentiation, suggesting the possible side effects of THZ1 on muscle function during treatment ([@b81-ol-0-0-11855]). CDK7i may also be combined with other anti-tumor drugs to improve efficacy and reduce side effects. In diffuse intrinsic pontine glioma, CDK7i has been found to disrupt transcriptional regulation in cancer cells; however, the sensitivity of cancer cells to CDK7i is notably increased when combined with histone deacetylase inhibitors ([@b79-ol-0-0-11855]).

The bromodomain and extra terminal (BET) family of bromodomain proteins (BRDs) consists of 4 members (BRD2, BRD3, BRD4 and BRDT) that may represent a promising new target for the discovery of small-molecule drugs ([@b82-ol-0-0-11855]). BRDs can recognize histone acetylation and promote the expression of corresponding genes, such as the MYC oncogene ([@b83-ol-0-0-11855]). Specifically, BET bromodomain inhibitor (BETi) mainly inhibits the binding function of BRD4, one of the mediator complexes of SE, thereby suppressing the expression of SE-driven oncogenes and attenuating the proliferation of cancer cells ([@b84-ol-0-0-11855]). However, it is still controversial whether the function of BETi depends on the expression of the MYC gene. Certain studies found BETi to preferentially affect the expression of the SE-driven MYC oncogene in multiple myeloma and colon cancer, suggesting that BETi sensitivity is significantly associated with c-MYC gene levels ([@b54-ol-0-0-11855],[@b61-ol-0-0-11855]). However, other studies reported contrasting results, as they did not observe a significant correlation between JQ1 sensitivity and c-MYC expression in colon cancer ([@b29-ol-0-0-11855]). Therefore, further research should be focused on maximizing the efficacy of BETi. In a study on pancreatic cancer, KDM6A was reported to mediate the abnormal activation of the SE regions of MYC and RUNX3 ([@b58-ol-0-0-11855]). When patients with pancreatic cancer, accompanied by KDM6A deficiency, were treated with BETi simultaneously, the selective sensitivity was observed. Severe BETi side effects have been reported in multiple phase I clinical trials, and include heart toxicity, gastrointestinal toxicity, anemia, diarrhea, fatigue, nausea, neutropenia and thrombocytopenia ([@b70-ol-0-0-11855],[@b85-ol-0-0-11855],[@b86-ol-0-0-11855]). For example, a BETi, I-BET-151, may even reduce the right and left ventricular fractional shortening, resulting in impaired heart function ([@b87-ol-0-0-11855]). The cytotoxicity of BETi caused serious side effects in clinical trials; however, the combination of this drug with vitamin C may largely alleviate those side effects ([@b88-ol-0-0-11855]).

In addition to the above two types of markedly effective and widely applicable drugs, there are other small-molecule drugs involved in blocking the function of SE. Attempting to abolish the SE function, the dynamic conversion between RACK7/KDM5C gene deletion and the accumulation of two SE formation-dependent methylation modifications (H3K4me1 and H3K4me3) provided a new approach to breast cancer therapy ([@b89-ol-0-0-11855]). Similarly, acetylation modifications have also been reported to be involved in the course of SE action. The IKAROS gene was usually undetectable in B cell line acute lymphoblastic leukemia; however, it has been demonstrated that the artificial overexpression of IKAROS gene can inhibit the expression of the MYC gene by interfering with the H3K27ac3 modification at the SE regions of MYC ([@b90-ol-0-0-11855]). PAX3 and PAX5 are the key TFs of the SE in pulmonary alveolar rhabdomyosarcoma and chronic lymphocytic leukemia, and PAX inhibitors have been found to exert prominent antitumor effects ([@b91-ol-0-0-11855],[@b92-ol-0-0-11855]). Another study proposed a novel paradigm for NF-κB-mediated gene inhibition, in which cofactors are redistributed and enriched through the accumulation of NF-κB at the SE regions ([@b93-ol-0-0-11855]). In addition to the key molecules mentioned above, other, novel small molecules that are considered to be SE-dependent in chordomas have gradually emerged, such as CDK9, CDK12 and CDK13 ([@b50-ol-0-0-11855]). In chordomas, the IRS4/IGF2 protein can directly interact with the SE sequence, thereby inhibiting the SE function detected by 4C-Seq assay ([@b50-ol-0-0-11855]). This phenomenon has been termed 'enhancer hijacking' and is widely reported in cancer. The development of these small-molecule inhibitors also provides promising therapeutic approaches against cancer.

Most of these drugs have expectant clinical application prospects, and some have entered the clinical trial phase ([Table II](#tII-ol-0-0-11855){ref-type="table"}).

Previous studies on antitumor drugs have focused on genomics, while drug design mainly focuses on the abnormal activation of proteins caused by mutations; however, this treatment is not without limitations ([@b94-ol-0-0-11855]). Drug resistance and low mutation frequency should not be overlooked in cancer ([@b95-ol-0-0-11855]). In recent years, with the development of epigenomics, methylation in the promoter region has been reported to regulate gene expression. Due to the common epigenetic modification reported in subsequent studies, designing drugs for this epigenetic mechanism is of great significance, which is considered as a better target ([@b96-ol-0-0-11855]). In the future, both universality and specificity should be taken into consideration in the direction of new drug design, such as the key process of SE regulation.

4.. Gene-editing targeting SE for cancer treatment
==================================================

The abnormal base insertion, base deletion and chromatin rearrangement in cancer cells can result in the formation of SE. CRISPR/Cas9 technology could be applied to abolish the SE formation caused by the aforementioned reasons. In addition, the objective of anticancer treatment can be achieved through the CRISPR/Cas9 system.

The CRISPR/Cas9 knockout system targets specific SE regions to cut DNA sequences, causing non-homologous recombination repair, thereby abolishing the SE function. RUNX1 is a transcription factor that regulates normal and malignant blood cell production. The disruption the SE regions of RUNX1 gene by the CRISPR/Cas9 system was shown to increase apoptosis in acute leukemia cells, and subsequently alter the survival of mice with acute myeloid leukemia (AML) ([@b97-ol-0-0-11855]). It was observed that, in T-cell acute lymphoblastic leukemia (T-ALL) primary samples and cell lines, an indel mutation occurred at the hotspot 7.5 kb upstream the transcription initiation site of the T-cell acute leukemia 1 (TAL1) gene and contributed to the formation of the MYB binding site and SE, thereby resulting in the upregulation of oncogenes ([@b98-ol-0-0-11855]). Following the knockout of the abnormally inserted bases by the CRISPR/Cas9 system, SE formation and TAL1 gene overexpression were absent in ALL ([@b98-ol-0-0-11855]). The transcription activator-like effector and CRISPR/Cas9 genome editing systems may also be used to abolish the activation of abnormal enhancers in AML cells. Subsequent experiments confirmed that gene-editing acting on enhancer efficiently inhibited the expression of ecotropic viral integration site 1 and cancer growth ([@b99-ol-0-0-11855]).

The CRISPR/Cas9 knock-in system is also promising in the SE-driven oncogene expression pattern associated with single-nucleotide polymorphisms (SNPs). It has been demonstrated that most trait-associated SNPs occur in non-coding regions, with 64% occurring in the disease-associated SE regions defined by H3K27ac ([@b7-ol-0-0-11855]). Subsequent studies revealed one underlying mechanism through which SNPs located within the SE regions could affect gene expression ([@b100-ol-0-0-11855],[@b101-ol-0-0-11855]). SNP rs6854845 is considered to be one of the risk factors for colon cancer ([@b102-ol-0-0-11855]). In colon cells, it was found that SNP rs6854845 formed in the SE region and affected the shifted enrichment of H3K4me1 and H3K27ac at the SE regions, further affecting the expression of SE-driven genes ([@b103-ol-0-0-11855]). The pathogenic SNP locus can be verified by expression quantitative trait locus, genomic chromatin interaction (high-throughput chromosome conformation capture), epigenetic annotation, and a series of functional assays ([@b104-ol-0-0-11855]). Therefore, the site-specific genome editing of SNPs by CRISPR/Cas9 can correct the multiple pathogenic changes in cells by reversing the interaction between SNPs and SE-associated genes.

Although the CRISPR technology is known for its effectiveness and versatility, it has two major drawbacks: The inability to arbitrarily edit bases and its off-target effects ([@b105-ol-0-0-11855]). The CRISPR/Cas9 system relies on the recognition of protospacer-adjacent motif (PAM) sites by single guide RNA to perform DNA shear, so the system can only edit DNA near the PAM site and cannot edit bases at any regions ([@b106-ol-0-0-11855]). As an important member of the CRISPR/Cas9 gene editing system, the Cas enzyme may cleave non-targeting sites after its introduction into cells, causing off-target effects ([@b107-ol-0-0-11855]). In addition, CRISPR/Cas9 gene editing relies on DNA double-stranded breaks, which may lead to an unpredictable disruption of cells following gene editing ([@b108-ol-0-0-11855]). These side effects of CRISPR/Cas9 limit their application in basic research and medicine, and may trigger safety issues.

A new precise gene editing tool, the Prime Editor, has been developed which can effectively convert all 12 single bases without relying on DNA templates and accurately insert or delete several bases ([@b109-ol-0-0-11855]). The Prime Editor system acts by combining Cas9 and reverse transcriptase into a complex, which is then brought to the specific DNA region to insert a new DNA sequence by the prime editing guide RNA (pegRNA) ([@b109-ol-0-0-11855]). This new method aims at improving the traditional cas9 enzyme and pegRNA to eliminate the 2 defects of the traditional CRISPR system. Through this new system, experiments in mouse cells have successfully repaired gene mutations that cause sickle cell anemia and Tay-Sachs disease ([@b109-ol-0-0-11855]). Sickle cell anemia is an autosomal dominant genetic disease, in which a single base mutation of A to T occurs in a gene encoding hemoglobin, resulting in the 6th amino acid glutamate of the hemoglobin β-peptide chain becoming valine, which makes the sickle hemoglobin replace the normal hemoglobin ([@b110-ol-0-0-11855]). Tay-Sachs disease is an autosomal recessive disorder in which the HEXA gene is mutated to an extra 4 bases, resulting in the inactivation of the lipolytic enzyme encoded by the HEXA gene, which in turn leads to the aggregation of gangliosides in the brain with ensuing toxicity ([@b111-ol-0-0-11855]). These genetic diseases could not be cured by traditional genome editing system, while the improved prime editor may prove more effective.

Although extensive animal and clinical experiments are required to further validate its safety and effectiveness, gene-editing therapy is already a promising method for tumor therapy. In conclusion, gene editing techniques are constantly being improved, and the prospects of the clinical application of these technologies in the near future are encouraging.

5.. Discussion
==============

SE is a controversial topic in current clinical and basic research, with great attention paid to its functions and potential therapeutic prospects in the clinic. With the improvement and breakthroughs made in next-generation sequencing technology, a more detailed and comprehensive understanding of the genome has emerged. By using the CRISPR/Cas9 system to interfere with the potential SE formation, the SE can be blocked to regulate the SE-driven oncogenes to avoid tumorigenesis. However, due to the off-target effects of the CRIPR/Cas9 system, it is impossible to accurately identify 100% of the human genome. Gene-editing at any non-target sites is associated with clinical risks. To date, the continuous improvement of CRISPR/Cas9 tools has not been effective in resolving the problem of off-target effects, causing great concerns regarding the safety of its clinical applications. The activation of SE is tightly linked to the interaction of certain key TFs. It has been reported that these key TFs play a critical role in cancer and further interference with small-molecule inhibitors also suppresses cancer cells ([@b5-ol-0-0-11855]). Since cancer cells are highly sensitive to SE-associated complexes, the inhibition of SE-derived gene expression is conceived as a safer and more promising therapeutic approach to cancer. The newly improved CAPTURE-Proteomics (ChIP-seq) technique is based on the core elements of CRISPR and adds biotin ligase BirA to improve the sensitivity and specificity of the experiment, which can more accurately detect the protein complex that binds to the SE site in order to find a new target for clinical small-molecule inhibitor therapy ([@b112-ol-0-0-11855]). Despite of the unclear mechanisms of SE and SE-associated complexes regulating the genome, the targeted therapy for SE-associated complexes remains one of the directions of treatment. With the persistent efforts focused on SE-associated complexes, greater breakthroughs are expected in the near future.
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![Schematic diagram of TE and SE function in transcriptional regulation. The TE promotes mRNA expression and the upregulation of miRNA and lncRNA, thereby promoting gene expression. The SE markedly promoted mRNA expression and the upregulation of miRNA and lncRNA, thereby increasing gene expression. TE, typical enhancer; SE, super-enhancer; miRNA, microRNA; lncRNA, long non-coding RNA; TSS, transcription start site.](ol-20-03-2557-g00){#f1-ol-0-0-11855}

![Schematic diagram of two methods for targeting SE complexes, small-molecule inhibitor and gene-editing small-molecule inhibitor that can target SE-associated complexes (such as BRD4 and CDK7), thereby destroying SE function. Gene-editing technology can knock out regions targeted by SE-associated complexes, thereby disrupting the SE function. SE, super-enhancer; BRD4, bromodomain protein 4; CDK7, cyclin-dependent kinase 7.](ol-20-03-2557-g01){#f2-ol-0-0-11855}

###### 

Examples of small-molecule inhibitors targeting super-enhancers in diseases.

  Small-molecule inhibitor            Target               Disease                                        Pubmed ID   (Refs.)
  ----------------------------------- -------------------- ---------------------------------------------- ----------- -----------------------
  THZ1                                CDK7                 Osteosarcoma                                   29644114    ([@b45-ol-0-0-11855])
  THZ1                                CDK7                 Thyroid carcinoma                              11158054    ([@b46-ol-0-0-11855])
  THZ1                                CDK7                 Neuroblastoma                                  25416950    ([@b21-ol-0-0-11855])
  THZ1                                CDK7                 Adult T-cell leukemia                          28978570    ([@b47-ol-0-0-11855])
  THZ1                                CDK7                 Melanoma                                       29408204    ([@b48-ol-0-0-11855])
  THZ1                                CDK7                 T-cell acute lymphoblastic leukemia            25043025    ([@b49-ol-0-0-11855])
  THZ1                                CDK7                 Small cell lung cancer                         25490451    ([@b8-ol-0-0-11855])
  THZ1                                CDK7, CDK12, CDK13   Chordoma                                       30664779    ([@b50-ol-0-0-11855])
  THZ531                              CDK12, CDK13         Chordoma                                       30664779    ([@b50-ol-0-0-11855])
  SY1365                              CDK7                 Ovarian and breast cancer                      31064851    ([@b51-ol-0-0-11855])
  NVP-2/AT7519/dinaciclib/alvocidib   CDK9                 Chordoma                                       30664779    ([@b50-ol-0-0-11855])
  JQ1                                 BRD4                 Cancer                                         28283057    ([@b35-ol-0-0-11855])
  JQ1                                 BRD4                 Cervical cancer                                27624132    ([@b52-ol-0-0-11855])
  JQ1                                 BRD4                 Merkel cell carcinoma                          25941994    ([@b53-ol-0-0-11855])
  JQ1                                 BRD4                 Multiple myeloma                               23582323    ([@b54-ol-0-0-11855])
  JQ1                                 BRD4                 Prostate and breast cancer                     28359301    ([@b55-ol-0-0-11855])
  JQ1                                 BRD4                 Colon cancer                                   28576751    ([@b29-ol-0-0-11855])
  JQ1                                 BRD4                 Diffuse large B-cell lymphoma                  24332044    ([@b56-ol-0-0-11855])
  JQ1                                 BRD4                 Hepatocellular carcinomas                      30659195    ([@b57-ol-0-0-11855])
  JQ1                                 BRD4                 Pancreatic cancer                              29533787    ([@b58-ol-0-0-11855])
  JQ1                                 BRD4                 Melanoma                                       28991225    ([@b59-ol-0-0-11855])
  JQ1                                 BRD4                 Cancer                                         27099234    ([@b60-ol-0-0-11855])
  JQ1                                 BRD4                 Colon cancer                                   26983878    ([@b61-ol-0-0-11855])
  JQ1                                 BRD4                 Adenoid cystic carcinoma                       26829750    ([@b62-ol-0-0-11855])
  JQ1                                 BRD4                 Blastic plasmacytoid dendritic cell neoplasm   27846392    ([@b63-ol-0-0-11855])
  JQ1                                 BRD4                 Breast cancer                                  30518851    ([@b64-ol-0-0-11855])
  JQ1                                 BRD4                 Melanoma                                       29149598    ([@b39-ol-0-0-11855])
  JQ1                                 BRD4                 Ovarian Cancer                                 26877780    ([@b65-ol-0-0-11855])
  JQ1                                 BRD4                 Large B-cell lymphoma                          25165099    ([@b66-ol-0-0-11855])
  JQ1                                 BRD4                 Lymphoma                                       23792448    ([@b67-ol-0-0-11855])
  JQ1                                 BRD4                 Acute myeloid leukemia                         26626481    ([@b68-ol-0-0-11855])
  I-BET151                            BRD4                 Blastic plasmacytoid dendritic cell neoplasm   27846392    ([@b63-ol-0-0-11855])
  I-BET151                            BRD4                 Ovarian cancer                                 26877780    ([@b65-ol-0-0-11855])
  I-BET762                            BRD2, BRD3, BRD4     Blastic plasmacytoid dendritic cell neoplasm   27846392    ([@b63-ol-0-0-11855])
  I-BET726                            BRD2, BRD3 BRD4      Acute myeloid leukemia                         28595007    ([@b69-ol-0-0-11855])
  OTX015                              BRD2, BRD3 BRD4      Leukemia                                       27063978    ([@b70-ol-0-0-11855])
  OTX015                              BRD2, BRD3 BRD4      Lymphoma                                       27063978    ([@b70-ol-0-0-11855])
  OTX015                              BRD2, BRD3 BRD4      Myeloma                                        27063978    ([@b70-ol-0-0-11855])
  CPI0610                             BRD4                 Hematological malignancies                     26815195    ([@b71-ol-0-0-11855])
  CPI0610                             BRD4                 Multiple myeloma                               27890933    ([@b72-ol-0-0-11855])
  CPI0610                             BRD4                 T-cell lymphoma                                30529073    ([@b73-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Breast cancer                                  28351928    ([@b74-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Melanoma                                       28351928    ([@b74-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Neuroblastoma                                  28351928    ([@b74-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Neuroblastoma                                  28432176    ([@b75-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Malignant rhabdoid tumor                       28432176    ([@b75-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Breast cancer                                  29229752    ([@b76-ol-0-0-11855])
  Ribociclib (LEE011)                 CDK4, CDK6           Breast cancer                                  28356261    ([@b77-ol-0-0-11855])

CDK, cyclin-dependent kinase; BRD, bromodomain protein.

###### 

Clinical trial information on various small molecule inhibitors.

  Small-molecule inhibitor   Clinical phase (clinical trial no.)   Disease
  -------------------------- ------------------------------------- -------------------------------------------------------------------------------------
  SY-1365                    Phase 1 (NCT03134638)                 Ovarian cancer, breast cancer, advanced solid tumors
  OTX015                     Phase 1 (NCT01713582)                 Acute myeloid leukemia
  OTX015                     Phase 1 (NCT01713582)                 Diffuse large B-cell lymphoma
  OTX015                     Phase 1 (NCT01713582)                 Acute lymphoblastic leukemia
  OTX015                     Phase 1 (NCT01713582)                 Multiple myeloma
  OTX015                     Phase 1 (NCT02259114)                 NUT midline carcinoma
  OTX015                     Phase 1 (NCT02259114)                 Triple negative breast cancer
  OTX015                     Phase 1 (NCT02259114)                 Non-small cell lung cancer with rearranged ALK gene/fusion protein or KRAS mutation
  OTX015                     Phase 1 (NCT02259114)                 Castrate-resistant prostate cancer
  OTX015                     Phase 1 (NCT02259114)                 Castration-resistant prostate cancer
  OTX015                     Phase 1 (NCT02259114)                 Pancreatic ductal adenocarcinoma
  OTX015                     Phase 2 (NCT02296476)                 Glioblastoma multiforme
  OTX015                     Phase 1 Phase 2 (NCT02303782)         Acute myeloid leukemia
  OTX015                     Phase 1 (NCT02698176)                 NUT midline carcinoma
  OTX015                     Phase 1 (NCT02698176)                 Triple negative breast cancer
  OTX015                     Phase 1 (NCT02698176)                 Non-small cell lung cancer
  OTX015                     Phase 1 (NCT02698176)                 Castration-resistant prostate cancer
  CPI0610                    Phase 2 (NCT02986919)                 Peripheral nerve tumors
  CPI0610                    Phase 1 (NCT01949883)                 Lymphoma
  CPI0610                    Phase 1 (NCT02157636)                 Multiple myeloma
  CPI0610                    Phase 2 (NCT02158858)                 Leukemia, myelocytic, acute
  LEE011                     Phase 2 (NCT02934568)                 Advanced cancer, advanced solid tumors
